AbCellera Biologics Inc. ABCL CA-BC — Government assistance, award amount, undrawn grant funding

Similar metrics at other companies

TSNGovernment assistance, award amount

$0—

MPDeferred government grant

$3.38M+24.1%

ONDSProceeds From Government Grant

$317+95.7%

KEYSGovernment assistance, asset, current

$5M-16.7%

AAONGrant proceeds received

$1.65M—

SHA

SHAZGrants receivable

$891.48K—

Other financials

Income statement

See full

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

See full

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

See full

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

See full

Market cap$1.84B+59.2%

Enterprise value$1.88B+100.0%

P/S23.3×-26.8×

Profitability

See full

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Returns & leverage

See full

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept abcl:GovernmentAssistanceAwardAmountUnusedBorrowingCapacity.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s ca-bc — government assistance, award amount, undrawn grant funding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbCellera Biologics Inc.'s CA-BC — government assistance, award amount, undrawn grant funding?: AbCellera Biologics Inc. (ABCL) reported CA-BC — government assistance, award amount, undrawn grant funding of $60.2M in Q1 2026.
What does CA-BC — government assistance, award amount, undrawn grant funding mean?: Indicates the total value of approved government grant funding available to the CA-BC segment that has not yet been drawn down. This represents a potential source of non-dilutive capital that can support future research and development initiatives.